VERELAN PM Rx
Generic Name and Formulations:
Verapamil HCl 100mg, 200mg, 300mg; controlled-onset ext-rel caps.
Indications for VERELAN PM:
Give once daily at bedtime. May sprinkle contents on applesauce; do not crush or chew contents. Initially 200mg; may titrate upwards in steps to 300mg, then 400mg if necessary. May start at 100mg in impaired renal or hepatic function, elderly or small patients.
Severe left ventricular (LV) dysfunction or LV dysfunction treated with β-blockers. Moderate to severe heart failure. Hypotension. Cardiogenic shock. Sick sinus syndrome, 2nd- or 3rd-degree AV block, unless paced. Atrial flutter or fibrillation and an accessory bypass tract.
Control mild heart failure (eg, with digitalis, diuretics). AV conduction or neuromuscular transmission disorders. Hepatic or renal dysfunction. Monitor liver function. Hypertrophic cardiomyopathy. Pregnancy (Cat.C). Nursing mothers: not recommended.
Calcium channel blocker (CCB) (diphenylalkylamine).
Potentiates alcohol, β-blockers, other antihypertensives, digitalis, ivabradine (avoid), theophylline, neuromuscular blockers, flecainide, carbamazepine, cyclosporine, doxorubicin. Potentiated by grapefruit juice. Avoid disopyramide; quinidine in cardiomyopathy. Potentiated by CYP3A4 inhibitors (eg, erythromycin, ritonavir); antagonized by CYP3A4 inducers (eg, rifampin, phenobarbital). May potentiate statins; limit simvastatin dose to 10mg/day or lovastatin to 40mg/day. May need to reduce initial and maintenance dose for other CYP3A4 substrates (eg, atorvastatin). Inhalation anesthetics may potentiate cardiac depression. May increase bleeding with aspirin. Monitor theophylline, lithium levels. Monitor heart rate when concomitant clonidine.
Hypotension, edema, AV block, bradycardia, CHF, constipation, headache, dizziness, fatigue, dyspepsia, elevated hepatic enzymes, paralytic ileus.
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes